Passage Bio, Inc. (PASG)
NCM · Healthcare · Biotechnology
Closing price as of 2026-07-29 · Source: TEK2day Finance
Key Metrics
About Passage Bio, Inc.
Passage Bio, Inc., a genetic medicines company, develops gene therapies for central nervous system diseases. It develops PBFT02, a functional granulin (GRN) and gene encoding progranulin (PGRN) for the treatment of FTD caused by progranulin deficiency; PBGM01, a functional GLB1 gene encoding ß-galactosidase for infantile GM1; and PBKR03, for the treatment of Krabbe disease. The company develops PBML04 for the treatment of metachromatic leukodystrophy; PBAL05 for the treatment of amyotrophic lateral sclerosis; and other programs for huntington's disease. It has a strategic research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program; and collaboration agreement, and a development services and clinical supply agreement with Catalent Maryland, Inc. Passage Bio, Inc. was incorporated in 2017 and is based in Philadelphia, Pennsylvania.
Quarterly Financials
| Metric | 2025-06-30 | 2025-09-30 | 2025-12-31 | 2026-03-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -10.3M | -8.7M | -10.3M | -8.9M |
| Net Income | -9.4M | -7.7M | -13.0M | -7.6M |
| Diluted EPS | $-2.96 | $-2.44 | $nan | $-2.36 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -135.4M | -103.0M | -65.2M | -43.2M |
| Net Income | -136.1M | -102.1M | -64.8M | -45.5M |
| Diluted EPS | $-50.00 | $-37.20 | $-21.40 | $-14.35 |